1 / 3

Comparisons of NETest Biomarker with CgA and Pancreastatin for Disease Diagnosis

This article examines the accuracy and effectiveness of the NETest biomarker in diagnosing diseases compared to CgA and Pancreastatin. Unlike Pancreastatin, NETest is not influenced by pancreas, kidney, or liver damage, making it highly accurate (>90%). The NETest outperforms CgA and Pancreastatin in terms of sensitivity, specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV). A clinically effective circulating biomarker must meet specific technical attributes, including easy detection, affordability, and strong association with a specific tumor. Accurate biomarker measurement that is reliable, reproducible, and differentiates between normal and diseased conditions is essential. The article emphasizes that all biomarker performance metrics should exceed 80%. Published in Nat Biotechnol 2010, 28431.

eshana
Télécharger la présentation

Comparisons of NETest Biomarker with CgA and Pancreastatin for Disease Diagnosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VII. Comparisons with Pancreastatin Porcine Pancreastatin UnlikePancreastatin The NETest is NOTincreased by pancreas, kidney or liver damage

  2. Comparisons of the NETest with CgA and Pancreastatin NETest is a highly accurate biomarker (>90% metrics) and outperforms CgA and pancreastatin SENS = sensitivity, SPEC = specificity, PPV = Positive Predictive Value, NPV = Negative Predictive Value

  3. What constitutes a clinically effective circulating biomarker? An effective circulating biomarker must exhibit three key technical attributes: The marker must be present in peripheral body fluid It must be easy to detect or quantify in assays that are both affordable and robust Its appearance must be associated as specifically as possible with a specific tumor, preferably in a quantifiable manner. Measurement of a biomarker should be accurate, reliable, reproducible and differentiate between normal and the specific disease of interest. All performance metrics should be >80% Biomarkers on a roll. Nat Biotechnol.2010, 28431

More Related